MedPath

Amiloride

Generic Name
Amiloride
Brand Names
Midamor
Drug Type
Small Molecule
Chemical Formula
C6H8ClN7O
CAS Number
2609-46-3
Unique Ingredient Identifier
7DZO8EB0Z3
Background

A pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with diuretics to spare potassium loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705)

Indication

For use as adjunctive treatment with thiazide diuretics or other kaliuretic-diuretic agents in congestive heart failure or hypertension.

Associated Conditions
Ascites, Calcium Nephrolithiasis, Congestive Heart Failure (CHF), Hypertension, Hypokalemia, Metabolic Alkalosis, Polyuria
Associated Therapies
-
Clinical Trials
Related News

DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease

Phase 4
Completed
Conditions
Chronic Kidney Disease
Interventions
Drug: Amiloride
Other: Low-sodium diet
Drug: Hydrochlorothiazide
First Posted Date
2016-08-23
Last Posted Date
2018-04-20
Lead Sponsor
Erasmus Medical Center
Target Recruit Count
28
Registration Number
NCT02875886
Locations
🇳🇱

ErasmusMC, Rotterdam, Netherlands

Comparison of Optimal Hypertension Regimens

First Posted Date
2016-07-28
Last Posted Date
2021-07-28
Lead Sponsor
Cambridge University Hospitals NHS Foundation Trust
Target Recruit Count
1320
Registration Number
NCT02847338
Locations
🇬🇧

Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom

🇬🇧

University Hospital Llandough, Cardiff, United Kingdom

🇬🇧

Queen Elizabeth Hospital, Birmingham, United Kingdom

and more 11 locations

Sequential Nephron Blockade vs. Dual Blockade Renin-angiotensin System + Bisoprolol in Resistant Arterial Hypertension

Phase 4
Completed
Conditions
Hypertension Resistant to Conventional Therapy
Interventions
Drug: Ramipril
Drug: Spironolactone
Drug: Furosemide,
Drug: Bisoprolol
Drug: Amiloride
First Posted Date
2016-07-14
Last Posted Date
2019-04-05
Lead Sponsor
Sao Jose do Rio Preto Medical School
Target Recruit Count
72
Registration Number
NCT02832973
Locations
🇧🇷

Juan Carlos Yugar-Toledo, São José do Rio Preto, São Paulo, Brazil

Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism

Phase 2
Completed
Conditions
Primary Hyperparathyroidism
Interventions
Drug: Placebo
Drug: amiloride
Drug: eplerenone
Drug: Cinacalcet
First Posted Date
2015-08-17
Last Posted Date
2023-05-03
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
69
Registration Number
NCT02525796
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

A Crossover Pilot Study of the Effect of Amiloride on Proteinuria

Phase 4
Conditions
Proteinuria
Interventions
Drug: Amiloride
Drug: Triamterene
First Posted Date
2015-08-13
Last Posted Date
2020-02-07
Lead Sponsor
Georgetown University
Target Recruit Count
30
Registration Number
NCT02522650
Locations
🇺🇸

Georgetown University, Washington, District of Columbia, United States

Vascular Effects of Mineralocorticoid Receptor Antagonism in Kidney Disease

Phase 2
Completed
Conditions
Chronic Kidney Disease
Albuminuria
Interventions
Drug: Spironolactone
Drug: Amiloride
First Posted Date
2015-07-14
Last Posted Date
2022-12-21
Lead Sponsor
University of Alabama at Birmingham
Target Recruit Count
21
Registration Number
NCT02497300
Locations
🇺🇸

Hypertension Research Clinic at UAB, Birmingham, Alabama, United States

Comparison of Single and Combination Diuretics in Low-Renin Hypertension

Phase 4
Conditions
Hypertension
Interventions
Drug: Hydrochlorthiazide
Drug: Amiloride
Drug: Hydrochlorthiazide and Amiloride
First Posted Date
2015-01-30
Last Posted Date
2015-07-03
Lead Sponsor
University of Cambridge
Target Recruit Count
423
Registration Number
NCT02351973
Locations
🇬🇧

Clinical Pharmacology Unit, Box 110, Level 3 ACCI, Addenbrookes Hospital, Cambridge, United Kingdom

Amiloride for Resistant Hypertension

Phase 4
Completed
Conditions
Hypertension
Type 2 Diabetes Mellitus
Microalbuminuria
Interventions
Drug: Amiloride
First Posted Date
2014-04-24
Last Posted Date
2014-04-24
Lead Sponsor
Ib Abildgaard Jacobsen
Target Recruit Count
80
Registration Number
NCT02122731
Locations
🇩🇰

Odense University Hospital, Department of Endocrinology, Odense, Denmark

🇩🇰

Sygehus Lillebaelt., Fredericia, Denmark

🇩🇰

Sydvestjysk Hospital, Esbjerg, Esbjerg, Denmark

and more 1 locations

Increased Activity of a Renal Salt Transporter (ENaC) in Diabetic Kidney Disease

Not Applicable
Conditions
Hypertension
Diabetic Nephropathies
Interventions
Dietary Supplement: Standardized salt diet
Drug: Amiloride
First Posted Date
2013-08-07
Last Posted Date
2013-10-16
Lead Sponsor
University of Southern Denmark
Target Recruit Count
80
Registration Number
NCT01918488
Locations
🇩🇰

Cardiovascular and Renal Research, Odense, Denmark

MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial

Phase 2
Completed
Conditions
Secondary Progressive Multiple Sclerosis
Interventions
Drug: Placebo
Drug: Riluzole
Drug: Amiloride
Drug: Fluoxetine
First Posted Date
2013-07-29
Last Posted Date
2020-03-26
Lead Sponsor
University College, London
Target Recruit Count
445
Registration Number
NCT01910259
Locations
🇬🇧

Gartnavel Royal Hospital, 1055 Great Western Road, Glasgow, United Kingdom

🇬🇧

The Walton Centre, Liverpool, United Kingdom

🇬🇧

Derriford Hospital, Plymouth, United Kingdom

and more 10 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy